UCB SA (UCBJY)
Develops medicines for brain and immune system disorders like epilepsy, Parkinson's, and rheumatoid arthritis
$142.43+0.02%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+32.9%
The outlook
UCBJY trades at 142.43, sitting below both its 50- and 200-day moving averages despite analyst consensus showing "Strong Buy" with an average target about 14% above the current price. The stock is positioned midway through its 52-week range and carries a trailing P/E of 30.6, reflecting a premium valuation.
What’s behind the score
Analyst consensusStrong Buy — 1.0 avg of 2 analysts
Price trendBelow its 50- & 200-day averages
52-week range58% of the way from its 52-week low to high
Price targetAvg target +14% vs current price
Analyst price target
~12-month · 2 analysts$162.21average target+13.9% vs now
Now $142.43
Low $160.15High $164.27
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$54.27B
52-wk high
$168.76
52-wk low
$105.40
50-day avg
$143.37
200-day avg
$144.72
Trailing P/E
30.6